Loading the company…
Loading the company…
Families: Peripheral nerve stimulation & intrathecal pumps, Bone graft & orthobiologics, Lumbar fusion.
All companies · Product and company coverage
Misonix's surgeons now deal with Bioventus. Integration brings new reps, contracts and bundles: for a competitor, a window while it settles; for Bioventus, surgeons to keep.
Bioventus press release · closing date to confirm
Payments and FDA records read by the company that owns the business today, so a deal never looks like surgeons switching; a surgeon’s payment history still shows the name each payment was made under.
In 2025, Bioventus reported engagement with 9,593 surgeons and other clinicians in the states MedaRep covers, worth $1.3M in consulting, speaking, meals and travel for its device products, the most in Connecticut ($214K to 142). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Connecticut ($214K, 142 engaged), Louisiana ($167K, 242 engaged), Florida ($160K, 885 engaged), Texas ($93K, 1,146 engaged), California ($83K, 940 engaged).
In the last ten years FDA made 6 decisions for Bioventus (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 3 procedure families, the most in 2025 (2). The latest was on 2026-08-26.
| Family | Decisions on record |
|---|---|
| Peripheral nerve stimulation & intrathecal pumps | 3 |
| Bone graft & orthobiologics | 3 |
| Lumbar fusion | 3 |
| SIGNAFUSE Bioactive Bone Graft |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Bioventus.